Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UPDATE 1-UK faces very difficult four weeks due to Omicron, health security agency says

Tue, 14th Dec 2021 12:36

(Adds details and quotes)

LONDON, Dec 14 (Reuters) - The Omicron variant of the novel
coronavirus is showing a higher rate of reinfection that other
variants and its growth rate is shortening in the United
Kingdom, the Health Security Agency's chief medical adviser said
on Tuesday.

"This is growing very fast with a growth rate of initially
two to three days, and that growth rate seems to be shortening
rather than lengthening," Dr Susan Hopkins said.

"We are concerned with the large volume of individuals who
are being infected every day in the population that we are going
to have a very difficult four weeks ahead with cases in the
community," she said.

"We are seeing a higher rate of reinfection than we've seen
before," Hopkins said.

Hopkins said infection from one variant of coronavirus
should protect against severe disease from another variant, but
it may not protect against mild disease or from transmission of
the virus.

Asked if an infection from the Omicron variant could bolster
immunity against the Delta variant, she replied: "There will be
protection, I think, from severe disease if you've had one
variant or the other, but these new variants may not protect you
from mild disease. And may not protect you from transmitting to
others."
(Reporting by Guy Faulconbridge and Kate Holton, Editing by
Paul Sandle)

Related Shares

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...

18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...

18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...

17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.